new glp 1 drug retatrutide Retatrutide—A Game Changer in Obesity Pharmacotherapy Retatrutide: A Promising Breakthrough for
Description
10.1056/NEJMc1615712 55 McDonaghT
doi: 10.1210/jc.2013-3766 102 StyrkarsdottirUTraganteVStefansdottirLThorleifssonGOddssonASrensenEet al
PIONEER 1: randomized clinical trial comparing the efficacy and safety of oral semaglutide monotherapy with placebo in patients with type 2 diabetes
PMID: 38398830
Given the frequent coexistence of HFpEF, obesity, and hypertension, the BP-lowering effects of GLP-1 RAs may be more advantageous in this setting
GLP-1s were added to the Essential Medicines List for diabetes but not for obesity, despite WHOs obesity treatment guidelines, published in December 2025, recommending their use
